InkredibleBuzz

Incredible Buzz traces its roots to Sunkwang Electronics, founded in 1991, and listed on KOSDAQ in 2002 as a distribution and marketing platform company.

Historically focused on fashion apparel and general merchandise distribution, the company has expanded into beauty, healthcare, and medical devices since its controlling shareholder changed to Human Wellness in 2024.

A partnership with Italy's Professional Dietetics to sell amino-acid-based beauty, therapeutic, and pet food products forms one pillar of the new business.

The company gained market visibility through its inner-beauty brand Nutracos, and according to reported figures, revenue in the third quarter of 2025 more than doubled year over year.

The company is awaiting regulatory approval for a bio-stimulator (skin booster) product called Suneco, which it expects to drive further growth.

Affiliate Motiva Korea holds the top market share in Korea's breast implant distribution market, while Incredible Buzz itself is focused on expanding its medical device distribution presence.

Controlling shareholder Human Wellness acquired KOSDAQ-listed Wingsfoot, a footwear distributor, in 2025, with Incredible Buzz and Motiva Korea co-investing, reportedly to leverage Wingsfoot's online and offline distribution networks.

There are also stated plans to expand Wingsfoot's role to diversify a business structure currently skewed toward beauty. Segment-level revenue breakdowns were not confirmed in available disclosures, so this description remains largely qualitative.

On confirmed annual results, 2025 consolidated revenue rose to KRW 7.21 billion from KRW 4.56 billion in 2024, but the operating loss widened to KRW 6.08 billion, an operating margin of -84.3%. Owner-attributable net income swung from a KRW 19.03 billion profit in 2024 to a KRW 30.20 billion loss in 2025.

In 2023, the company posted revenue of KRW 6.90 billion, an operating loss of KRW 0.57 billion, and a net loss of KRW 6.99 billion, while in 2022 it recorded a much larger loss profile with revenue of KRW 29.37 billion, an operating loss of KRW 13.23 billion, and a net loss of KRW 14.99 billion, coinciding with the wind-down of its legacy luxury and fashion distribution business.

Owner's equity surged from KRW 3.71 billion in 2022 to KRW 36.29 billion in 2023 and KRW 96.83 billion in 2024, before declining to KRW 66.79 billion in 2025, reflecting a mix of repeated rights offerings, convertible bond issuance, and large net losses.

The debt ratio fell from 133.1% in 2022 to 66.0% in 2023, then to 3.1% in 2024 and 6.2% in 2025, remaining low.

Over the latest four quarters, revenue fell sequentially from KRW 2.01 billion (2025Q3) to KRW 1.71 billion (2025Q4), KRW 1.45 billion (2026Q1), and KRW 0.62 billion (2026Q2), suggesting the first-half trading suspension weighed on operations.

Operating losses continued throughout at KRW 1.56 billion, KRW 1.77 billion, KRW 3.00 billion, and KRW 1.80 billion respectively, while owner-attributable net losses persisted at KRW 4.50 billion, KRW 6.00 billion, KRW 5.12 billion, and KRW 1.79 billion after an especially large KRW 10.78 billion loss in 2025Q2.

FnGuide noted that cumulative revenue through the third quarter of 2025 rose 128.2% year over year, but the operating loss also expanded 105.6%, indicating revenue growth has not translated into improved profitability.

The skin-booster (bio-stimulator) market the company has entered is growing on trends such as the "old money" look and "clean girl" makeup, with the global market estimated to grow at roughly a 10% annual rate to reach about $2.1 billion by 2030 according to industry commentary.

The broader luxury and beauty distribution market is diversifying its consumer base through social media effects, with companies focusing on online marketing to improve results.

The company was reported to have pursued acquisitions of K-beauty distribution businesses with the stated ambition of becoming a "second Silicon2,

The most immediate item to track is the outcome of the injunction petition filed with the Seoul Southern District Court seeking to suspend the effect of the delisting decision.

That ruling will determine whether the trading suspension continues, whether the previously scheduled liquidation trading (originally set for July 6–14, 2026) and final delisting (originally set for July 15, 2026) resume, or whether other market measures are taken.

Management has stated it intends to continue the healthcare, medical-device, and platform-centered business realignment pursued since the second half of 2024, and the CEO indicated in early 2026 an expectation of further growth and profitability stabilization once the pending Suneco product receives regulatory approval.

However, the recurrence of a disclaimer opinion tied to related-party transactions in the August 2026 half-year review suggests similar issues could resurface in upcoming third-quarter results and the annual audit report.

On the governance side, former CEO Lim Shin-young's board resignation, related breach-of-trust litigation, and the unresolved equity and funding flows around subsidiary Incredible Daebu remain variables to monitor.

A key point of observation is how well the company's stated conditions for resuming trading—management continuity, business sustainability, and tangible turnaround performance—are substantiated by future disclosures and results.